摘要
目前预防艾滋病的行为干预方法(如安全套的推广、清洁针具的交换等)并不一定普及或适用于每个具有高危行为的人,新型生物干预策略有可能成为目前艾滋病预防的一项重要措施。暴露前使用抗逆转录病毒(anti-retrovrial,ARV)药物作为一种新型生物干预策略现已受到广泛关注。高危人群在发生HIV感染的高危行为(暴露)前口服ARV药物有可能成为预防HIV感染的一种有效方法。研究暴露前预防性用药的安全性、有效性、可接受性及其与艾滋病感染、高危行为之间的关系,对于将来此类药物的研发和应用有一定的指导意义。本文就暴露前使用抗病毒药预防艾滋病的必要性与可行性、实施此项策略面临的挑战以及可能产生的潜在效应做一综述。
The current behavior intervention of HIV prevention such as the promotion of condoms use and clean needle exchange may not suitable or available for every high-risk individuals.Biomedical chemoprophylaxis may be an important measure in the prevention of HIV infection.As a new biomedical intervention strategy,pre-exposure use of anti-retroviral（ARV） drugs has been of widespread concern.Oral administration of ARV drugs before high-risk behaviors（pre-exposure） in high-risk populations could be an effective method in the prevention of HIV infection.To study the safety,effectiveness,acceptability of PrEP and its relationship with HIV infection and high-risk behavior has important directive significance on the future development and application of this kind of drug.This paper is a review of the necessity and practicability,the challenges of its application and the potential effect of PrEP.
出处
《中华疾病控制杂志》
CAS
2011年第2期156-160,共5页
Chinese Journal of Disease Control & Prevention
基金
国家“十一五艾滋病和病毒性肝炎等重大传染病防治”科技重大专项项目(2009ZX10004-903)
